[go: up one dir, main page]

AR095426A1 - Inhibidores tripeptídicos de la epoxicetona proteasa - Google Patents

Inhibidores tripeptídicos de la epoxicetona proteasa

Info

Publication number
AR095426A1
AR095426A1 ARP140100970A ARP140100970A AR095426A1 AR 095426 A1 AR095426 A1 AR 095426A1 AR P140100970 A ARP140100970 A AR P140100970A AR P140100970 A ARP140100970 A AR P140100970A AR 095426 A1 AR095426 A1 AR 095426A1
Authority
AR
Argentina
Prior art keywords
group
alkyl
halo
independently
substituents
Prior art date
Application number
ARP140100970A
Other languages
English (en)
Original Assignee
Onyx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51581125&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR095426(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Onyx Therapeutics Inc filed Critical Onyx Therapeutics Inc
Priority to ARP140100970A priority Critical patent/AR095426A1/es
Priority to HRP20171572TT priority patent/HRP20171572T1/hr
Priority to DK14722443.0T priority patent/DK2970224T3/en
Priority to PE2015001916A priority patent/PE20151558A1/es
Priority to LTEP14722443.0T priority patent/LT2970224T/lt
Priority to JP2016502301A priority patent/JP6483657B2/ja
Priority to SM20170505T priority patent/SMT201700505T1/it
Priority to ES14722443.0T priority patent/ES2642765T3/es
Priority to RS20171125A priority patent/RS56500B1/sr
Priority to EA201591751A priority patent/EA029548B1/ru
Priority to HK16101100.7A priority patent/HK1213249B/xx
Priority to PT147224430T priority patent/PT2970224T/pt
Priority to PCT/US2014/026987 priority patent/WO2014152134A1/en
Priority to MX2019007950A priority patent/MX390369B/es
Priority to EP14722443.0A priority patent/EP2970224B1/en
Priority to US14/210,806 priority patent/US9434761B2/en
Priority to KR1020157029310A priority patent/KR102365509B1/ko
Priority to CN201480022700.9A priority patent/CN105143212B/zh
Priority to SI201430467T priority patent/SI2970224T1/sl
Priority to AU2014240129A priority patent/AU2014240129B2/en
Priority to MX2015011766A priority patent/MX366200B/es
Priority to HUE14722443A priority patent/HUE034769T2/en
Priority to CA2903720A priority patent/CA2903720C/en
Priority to PL14722443T priority patent/PL2970224T3/pl
Priority to MEP-2017-255A priority patent/ME02912B/me
Priority to SG11201507033RA priority patent/SG11201507033RA/en
Priority to NZ711715A priority patent/NZ711715B2/en
Priority to BR112015023298-1A priority patent/BR112015023298B1/pt
Priority to IL24117015A priority patent/IL241170B/en
Priority to ZA2015/06572A priority patent/ZA201506572B/en
Priority to PH12015502002A priority patent/PH12015502002B1/en
Priority to SA515361045A priority patent/SA515361045B1/ar
Priority to CL2015002706A priority patent/CL2015002706A1/es
Publication of AR095426A1 publication Critical patent/AR095426A1/es
Priority to US15/251,688 priority patent/US10647744B2/en
Priority to US15/631,276 priority patent/USRE47302E1/en
Priority to CY20171101263T priority patent/CY1119645T1/el
Priority to US16/818,731 priority patent/US11078233B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/32—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by aldehydo- or ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C07K5/06069—Ser-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C07K5/06113—Asp- or Asn-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C07K5/06113—Asp- or Asn-amino acid
    • C07K5/06121—Asp- or Asn-amino acid the second amino acid being aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06147—Dipeptides with the first amino acid being heterocyclic and His-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06173—Dipeptides with the first amino acid being heterocyclic and Glp-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C07K5/0823—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp and Pro-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)

Abstract

Se proporcionan en la presente inhibidores tripeptídicos de epoxi cetona proteasa, métodos para su preparación, composiciones farmacéuticas relacionadas y métodos de uso de ellos. Los compuestos y composiciones proporcionados en la presente se pueden usar, por ejemplo, en el tratamiento de enfermedades que incluyen inflamación y enfermedad neurodegenerativa. Reivindicación 1: Un compuesto de la fórmula (1) en donde: m y n son cada uno, de modo independiente, 0, 1 ó 2 y m + n = 2, 3 ó 4; p es 0 ó 1; q es 0, 1 ó 2; K está seleccionado del grupo que consiste en CR⁵R⁶, NR⁷, N(C=O)OR⁷, -NH-(C=O)-, O, S, SO y SO₂; E es N o CR⁷; R¹ está seleccionado del grupo que consiste en H, alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, cicloalquilo C₃₋₆, y heterocicloalquilo de 3 - 6 miembros, en donde R¹ está opcionalmente sustituido con uno o varios sustituyentes seleccionados del grupo que consiste en halo, OR⁷, SR⁷, N(R⁷)₂, CN y (C=O)N(R⁷)₂; R² es alquilen C₁₋₂-G o (C=O)-G; en donde G está seleccionado del grupo que consiste en arilo, heteroarilo y piridinona, siempre que cuando R² es CH₂-fenilo, el fenilo esté sustituido con uno o varios sustituyentes seleccionados del grupo que consiste en OR⁷, halo, alquilo C₁₋₃, OCF₃, SO₂R⁷, (C=O)N(R⁷)₂, CN y SO₂N(R⁷)₂; R³ está seleccionado del grupo que consiste en cicloalquilo C₃₋₇, cicloalquenilo C₃₋₇, un heterocicloalquilo de 3 - 7 miembros y un heterocicloalquenilo de 3 - 7 miembros, en donde R³ está opcionalmente sustituido con uno o varios sustituyentes seleccionados del grupo que consiste en halo, =O, OR⁷, SR⁷, N(R⁷)₂, O(C=O)N(R⁷)₂ y alquilo C₁₋₆; R⁴ es H o alquilo C₁₋₃; R⁵ y R⁶ están seleccionados, cada uno de modo independiente, del grupo que consiste en H, OH, halo, alquilo C₁₋₃ y CF₃ o R⁵ y R⁶ junto con el carbono al que están unidos forman C=O o un resto de fórmula (2), en donde W es O ó NR⁷ y r es 1, 2 ó 3; y cada R⁷ es, de modo independiente, H o alquilo C₁₋₆; o una de sus sales farmacéuticamente aceptables.
ARP140100970A 2013-03-14 2014-03-13 Inhibidores tripeptídicos de la epoxicetona proteasa AR095426A1 (es)

Priority Applications (37)

Application Number Priority Date Filing Date Title
ARP140100970A AR095426A1 (es) 2013-03-14 2014-03-13 Inhibidores tripeptídicos de la epoxicetona proteasa
BR112015023298-1A BR112015023298B1 (pt) 2013-03-14 2014-03-14 Inibidores tripeptídicos da epóxi cetona protease
SI201430467T SI2970224T1 (sl) 2013-03-14 2014-03-14 Tripeptidni epoksi ketonski proteazni inhibitorji
AU2014240129A AU2014240129B2 (en) 2013-03-14 2014-03-14 Tripeptide epoxy ketone protease inhibitors
PE2015001916A PE20151558A1 (es) 2013-03-14 2014-03-14 Inhibidores tripeptidicos de la epoxicetona proteasa
LTEP14722443.0T LT2970224T (lt) 2013-03-14 2014-03-14 Tripeptido epoksi ketono proteazės inhibitoriai
JP2016502301A JP6483657B2 (ja) 2013-03-14 2014-03-14 トリペプチドエポキシケトンプロテアーゼ阻害剤
HUE14722443A HUE034769T2 (en) 2013-03-14 2014-03-14 Tripeptide epoxy ketone protease inhibitors
ES14722443.0T ES2642765T3 (es) 2013-03-14 2014-03-14 Inhibidores de proteasa de epoxi cetona tripeptídica
RS20171125A RS56500B1 (sr) 2013-03-14 2014-03-14 Tripeptidi kao inhibitori epoksi ketona
EA201591751A EA029548B1 (ru) 2013-03-14 2014-03-14 Трипептидные эпоксикетонные ингибиторы протеазы
HK16101100.7A HK1213249B (en) 2013-03-14 2014-03-14 Tripeptide epoxy ketone protease inhibitors
PT147224430T PT2970224T (pt) 2013-03-14 2014-03-14 Tripéptidos inibidores da epoxi cetona protéase
PCT/US2014/026987 WO2014152134A1 (en) 2013-03-14 2014-03-14 Tripeptide epoxy ketone protease inhibitors
MX2019007950A MX390369B (es) 2013-03-14 2014-03-14 Inhibidores tripeptidicos de la epoxicetona proteasa
EP14722443.0A EP2970224B1 (en) 2013-03-14 2014-03-14 Tripeptide epoxy ketone protease inhibitors
US14/210,806 US9434761B2 (en) 2013-03-14 2014-03-14 Tripeptide epoxy ketone protease inhibitors
KR1020157029310A KR102365509B1 (ko) 2013-03-14 2014-03-14 트리펩타이드 에폭시 케톤 프로테이스 억제제
CN201480022700.9A CN105143212B (zh) 2013-03-14 2014-03-14 三肽环氧酮蛋白酶抑制剂
HRP20171572TT HRP20171572T1 (hr) 2013-03-14 2014-03-14 Tripeptidi kao inhibitori epoksi keton proteaze
MX2015011766A MX366200B (es) 2013-03-14 2014-03-14 Inhibidores tripeptidicos de la epoxicetona proteasa.
DK14722443.0T DK2970224T3 (en) 2013-03-14 2014-03-14 TRIPEPTIDEPOXYKETONE PROTEASE INHIBITORS
SM20170505T SMT201700505T1 (it) 2013-03-14 2014-03-14 Tripeptidi inibitori delle proteasi di epossichetoni
CA2903720A CA2903720C (en) 2013-03-14 2014-03-14 Tripeptide epoxy ketone protease inhibitors
PL14722443T PL2970224T3 (pl) 2013-03-14 2014-03-14 Tripeptydoepoksyketonowe inhibitory proteaz
MEP-2017-255A ME02912B (me) 2013-03-14 2014-03-14 Tripeptidi kao inhibitori epoksi keton proteaze
SG11201507033RA SG11201507033RA (en) 2013-03-14 2014-03-14 Tripeptide epoxy ketone protease inhibitors
NZ711715A NZ711715B2 (en) 2013-03-14 2014-03-14 Tripeptide epoxy ketone protease inhibitors
IL24117015A IL241170B (en) 2013-03-14 2015-09-03 Epoxy ketone tripeptide protease inhibitors
ZA2015/06572A ZA201506572B (en) 2013-03-14 2015-09-07 Tripeptide epoxy ketone protease inhibitors
PH12015502002A PH12015502002B1 (en) 2013-03-14 2015-09-08 Tripeptide epoxy ketone protease inhibitors
SA515361045A SA515361045B1 (ar) 2013-03-14 2015-09-10 مثبطات إيبوكسي كيتون بروتياز ثلاثي الببتيد
CL2015002706A CL2015002706A1 (es) 2013-03-14 2015-09-14 Inhibidores tripeptídicos de la epoxicetona proteasa.
US15/251,688 US10647744B2 (en) 2013-03-14 2016-08-30 Tripeptide epoxy ketone protease inhibitors
US15/631,276 USRE47302E1 (en) 2013-03-14 2017-06-23 Peptide epoxyketone immunoproteasome inhibitors
CY20171101263T CY1119645T1 (el) 2013-03-14 2017-12-01 Τριπεπτιδικοι αναστολεις πρωτεασης εποξειδικης κετονης
US16/818,731 US11078233B2 (en) 2013-03-14 2020-03-13 Tripeptide epoxy ketone protease inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361785608P 2013-03-14 2013-03-14
ARP140100970A AR095426A1 (es) 2013-03-14 2014-03-13 Inhibidores tripeptídicos de la epoxicetona proteasa

Publications (1)

Publication Number Publication Date
AR095426A1 true AR095426A1 (es) 2015-10-14

Family

ID=51581125

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140100970A AR095426A1 (es) 2013-03-14 2014-03-13 Inhibidores tripeptídicos de la epoxicetona proteasa

Country Status (28)

Country Link
US (4) US9434761B2 (es)
EP (1) EP2970224B1 (es)
JP (1) JP6483657B2 (es)
CN (1) CN105143212B (es)
AR (1) AR095426A1 (es)
AU (1) AU2014240129B2 (es)
BR (1) BR112015023298B1 (es)
CA (1) CA2903720C (es)
CL (1) CL2015002706A1 (es)
CY (1) CY1119645T1 (es)
DK (1) DK2970224T3 (es)
EA (1) EA029548B1 (es)
ES (1) ES2642765T3 (es)
HR (1) HRP20171572T1 (es)
HU (1) HUE034769T2 (es)
IL (1) IL241170B (es)
LT (1) LT2970224T (es)
ME (1) ME02912B (es)
MX (1) MX366200B (es)
PE (1) PE20151558A1 (es)
PH (1) PH12015502002B1 (es)
PL (1) PL2970224T3 (es)
PT (1) PT2970224T (es)
RS (1) RS56500B1 (es)
SG (1) SG11201507033RA (es)
SI (1) SI2970224T1 (es)
WO (1) WO2014152134A1 (es)
ZA (1) ZA201506572B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014230814B2 (en) 2013-03-14 2017-12-21 Boehringer Ingelheim International Gmbh Substituted 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of Cathepsin C
AR095426A1 (es) 2013-03-14 2015-10-14 Onyx Therapeutics Inc Inhibidores tripeptídicos de la epoxicetona proteasa
AU2015229174B2 (en) 2014-03-13 2019-04-11 Assembly Biosciences, Inc. Hepatitis B core protein allosteric modulators
KR102510588B1 (ko) 2014-09-12 2023-03-17 베링거 인겔하임 인터내셔날 게엠베하 카텝신 c의 스피로사이클릭 억제제
TWI786639B (zh) 2015-09-15 2022-12-11 美商艾森伯利生物科學公司 B型肝炎核心蛋白質調節劑
US10836756B2 (en) * 2016-06-29 2020-11-17 Kezar Life Sciences Crystalline salts of peptide epoxyketone immunoproteasome inhibitor
EP4296257A3 (en) 2016-06-29 2024-03-20 Kezar Life Sciences Process of preparing a peptide epoxyketone immunoproteasome inhibitor
CN107417767B (zh) * 2016-08-18 2021-09-03 杭州市西溪医院 哌啶或哌嗪构建的二肽化合物、其制备方法和应用
WO2018053157A1 (en) 2016-09-15 2018-03-22 Assembly Biosciences, Inc. Hepatitis b core protein modulators
MX2019010404A (es) 2017-03-02 2019-11-21 Assembly Biosciences Inc Compuestos sulfamida cíclicos y métodos de uso de los mismos.
SG11201908475RA (en) 2017-03-13 2019-10-30 Assembly Biosciences Inc Process for making hepatitis b core protein modulators
US11357817B2 (en) 2017-05-15 2022-06-14 The Regents Of The University Of California Immunoproteasome inhibitor
JP7289828B2 (ja) * 2017-08-23 2023-06-12 ケザール ライフ サイエンシズ 自己免疫疾患の治療における免疫プロテアソーム阻害剤および免疫抑制剤
US20200276204A1 (en) 2017-09-21 2020-09-03 Kezar Life Sciences Combination therapy for immunological diseases
WO2020033437A1 (en) 2018-08-06 2020-02-13 University Of Kentucky Research Foundation Proteasome inhibitors
MX2021003899A (es) 2018-10-04 2021-06-04 Kezar Life Sciences Formulaciones de inhibidores de inmunoproteasomas.
CN110078643A (zh) * 2019-05-27 2019-08-02 吉尔生化（上海）有限公司 一种Nα-叔丁氧羰基-DL-间羟基酪氨酸的合成方法
CN110204500A (zh) * 2019-07-17 2019-09-06 九江德思光电材料有限公司 一种叶菌唑的制备方法
US20230159586A1 (en) * 2020-04-21 2023-05-25 University Of Rochester Inhibitors of human epididymus protein 4
CN111440079B (zh) * 2020-04-29 2024-03-08 山东普洛汉兴医药有限公司 一种dl-苏式-对氯苯丝氨酸的合成方法
CN115322130B (zh) * 2022-08-02 2024-05-14 南京正济医药研究有限公司 制备(s)-2-(boc-氨基)-3-[(s)-2-氧代-3-吡咯烷基]丙酸甲酯
CN115124634B (zh) * 2022-08-10 2023-10-20 杭州小菱科技有限公司 一种茂金属主催化剂及其制备方法
CN115650881B (zh) * 2022-09-06 2025-01-17 浙江医药股份有限公司新昌制药厂 一种利用微反应器合成喹诺酮类化合物中间体的工艺方法
WO2024140736A1 (zh) * 2022-12-27 2024-07-04 上海美悦生物科技发展有限公司 三肽环氧酮化合物、药物组合物及其制备方法和用途
CN116768972A (zh) * 2023-06-25 2023-09-19 重庆药友制药有限责任公司 一种卡非佐米中间体的制备方法
GB202312279D0 (en) * 2023-08-10 2023-09-27 Univ Leiden New compounds and uses
WO2025067199A1 (zh) * 2023-09-26 2025-04-03 上海齐鲁制药研究中心有限公司 免疫蛋白酶体选择性抑制剂
WO2025092827A1 (zh) * 2023-10-30 2025-05-08 上海汇伦医药股份有限公司 一种环氧类化合物及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5340736A (en) 1991-05-13 1994-08-23 The President & Fellows Of Harvard College ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
WO1998010779A1 (en) 1996-09-13 1998-03-19 New York University Method for treating parasitic diseases with proteasome inhibitors
US6042820A (en) 1996-12-20 2000-03-28 Connaught Laboratories Limited Biodegradable copolymer containing α-hydroxy acid and α-amino acid units
US6472375B1 (en) 1998-04-16 2002-10-29 John Wayne Cancer Institute DNA vaccine and methods for its use
RU2355700C9 (ru) * 2000-07-21 2010-03-20 Шеринг Корпорейшн Новые пептиды как ингибиторы ns3-серинпротеазы вируса гепатита с
US7232818B2 (en) 2004-04-15 2007-06-19 Proteolix, Inc. Compounds for enzyme inhibition
CA2565407A1 (en) * 2004-05-10 2005-11-24 Proteolix, Inc. Compounds for enzyme inhibition
ES2549763T3 (es) 2004-12-07 2015-11-02 Onyx Therapeutics, Inc. Composición para inhibición del proteasoma
WO2006099261A2 (en) 2005-03-11 2006-09-21 The University Of North Carolina At Chapel Hill Potent and specific immunoproteasome inhibitors
KR101434522B1 (ko) 2005-11-09 2014-08-26 오닉스 세라퓨틱스, 인크. 효소 저해를 위한 화합물
US7691852B2 (en) 2006-06-19 2010-04-06 Onyx Therapeutics, Inc. Compounds for enzyme inhibition
JP5675629B2 (ja) 2008-10-21 2015-02-25 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ペプチドエポキシケトンを用いた併用療法
MY165002A (en) 2012-05-08 2018-02-28 Onyx Therapeutics Inc Cylodextrin complexation methods for formulating peptide proteasome inhibitors
AR095426A1 (es) * 2013-03-14 2015-10-14 Onyx Therapeutics Inc Inhibidores tripeptídicos de la epoxicetona proteasa

Also Published As

Publication number Publication date
EA201591751A1 (ru) 2016-04-29
PH12015502002B1 (en) 2021-03-24
PE20151558A1 (es) 2015-11-24
NZ711715A (en) 2020-12-18
CL2015002706A1 (es) 2016-04-22
SI2970224T1 (sl) 2017-12-29
IL241170B (en) 2019-11-28
WO2014152134A1 (en) 2014-09-25
RS56500B1 (sr) 2018-01-31
HRP20171572T1 (hr) 2017-12-15
IL241170A0 (en) 2015-11-30
US9434761B2 (en) 2016-09-06
BR112015023298A2 (pt) 2017-07-18
ZA201506572B (en) 2016-10-26
ES2642765T3 (es) 2017-11-20
AU2014240129B2 (en) 2018-05-31
LT2970224T (lt) 2017-12-11
US20160368946A1 (en) 2016-12-22
JP6483657B2 (ja) 2019-03-13
CY1119645T1 (el) 2018-04-04
JP2016515509A (ja) 2016-05-30
BR112015023298B1 (pt) 2023-05-09
HUE034769T2 (en) 2018-02-28
AU2014240129A1 (en) 2015-09-24
CA2903720A1 (en) 2014-09-25
EP2970224A1 (en) 2016-01-20
US20140336106A1 (en) 2014-11-13
CN105143212B (zh) 2018-02-23
EP2970224B1 (en) 2017-09-06
DK2970224T3 (en) 2017-10-16
PH12015502002A1 (en) 2016-01-11
SG11201507033RA (en) 2015-10-29
EA029548B1 (ru) 2018-04-30
USRE47302E1 (en) 2019-03-19
US10647744B2 (en) 2020-05-12
PL2970224T3 (pl) 2018-05-30
US11078233B2 (en) 2021-08-03
MX2015011766A (es) 2016-01-15
PT2970224T (pt) 2017-11-14
MX366200B (es) 2019-07-02
ME02912B (me) 2018-10-20
HK1213249A1 (zh) 2016-06-30
CN105143212A (zh) 2015-12-09
CA2903720C (en) 2021-05-11
US20200207809A1 (en) 2020-07-02

Similar Documents

Publication Publication Date Title
AR095426A1 (es) Inhibidores tripeptídicos de la epoxicetona proteasa
AR119454A2 (es) COMPUESTOS ÚTILES COMO MODULADORES DE RORg, SALES FARMACÉUTICAMENTE ACEPTABLES DE LOS MISMOS, COMPOSICIONES FARMACÉUTICAS Y DICHOS COMPUESTOS PARA USO COMO MEDICAMENTO
CR20170116A (es) Compuestos que inhiben la proteina mcl-1
MX385158B (es) Derivados indol para uso en medicina.
SV2016005229A (es) Inhibidores de syk
PE20160678A1 (es) Inhibidores marcados de antigeno prostatico especifico de membrana (psma), su uso como agentes formadores de imagenes y agentes farmaceuticos para el tratamiento de cancer de prostata
AR103561A1 (es) Fenilpiridinas herbicidas
AR114971A1 (es) Compuestos de purinona y su uso en el tratamiento del cáncer
AR094964A1 (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRASTORNOS RELACIONADOS CON LA FOSFOINOSITIDA 3-CINASA d (PI3Kd)
AR103138A1 (es) Compuestos de heteroarilo como inhibidores de la irak y usos de los mismos
AR095192A1 (es) Quinolina y quinazolinamidas como modulares de canales de sodio
BR112015021983A8 (pt) compostos heterocíclicos, composições e usos dos mesmos
AR097325A1 (es) Pirroles anillados
AR106865A1 (es) Piridinas sustituidas y métodos de uso
AR077080A1 (es) Compuestos de 2,3-dihidro-1h-indeno
PE20170303A1 (es) Derivados de la indolizina como inhibidores de las fosfoinositido-3 quinasas
AR098776A1 (es) Derivados del isocromeno como inhibidores de las fosfoinositido-3 quinasas
AR097894A1 (es) Inhibidores terapéuticos de cdk8 o uso de los mismos
AR100073A1 (es) Sulfonas heterocíclicas sustituidas con heteroarilos
CU20160010A7 (es) NUEVOS COMPUESTOS ISOINDOLlNA O ISOQUINOLlNA ÚTILES COMO INHIBIDORES ANTIAPOPTÓTICOS Bcl-2 Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
CL2019001041A1 (es) Compuestos terapéuticos y métodos para utilizarlos.
AR101479A1 (es) Derivados de 6-alquinil-piridina
AR101528A1 (es) Inhibidores de cdk9 quinasa de pirrolo[2,3-b]piridina
AR101395A1 (es) Derivados de indolizina y su uso en enfermedades neurodegenerativas
CY1125355T1 (el) Πεντακυκλικη ενωση

Legal Events

Date Code Title Description
FG Grant, registration